ClinicalTrials.Veeva

Menu

A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) (RESTORE)

Ono Pharmaceuticals logo

Ono Pharmaceuticals

Status and phase

Completed
Phase 2

Conditions

Irritable Bowel Syndrome (IBS)

Treatments

Drug: ONO-2952
Drug: ONO-2952 Matching Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT01844180
ONO-2952POU004

Details and patient eligibility

About

The objective of this study is to explore efficacy, safety and tolerability of ONO-2952 in female subjects with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D).

Enrollment

200 patients

Sex

Female

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Female 18-65 years of age (inclusive)

  2. Diagnosed with IBS based on the following criteria (Rome III criteria):

    • Symptom onset at least 6 months prior to diagnosis, and

    • Recurrent abdominal pain or discomfort at least 3 days per month for the past 3 months, and

    • Abdominal discomfort or pain associated with two or more of the following at least 25% of the time:

      1. Improvement with defecation
      2. Onset associated with a change in frequency of stool/defecation
      3. Onset associated with a change in form (appearance) of stool
  3. Diagnosed with IBS-D, defined as loose/watery stools ≥ 25% and hard/lumpy stools ≤ 25% of defecations

Exclusion criteria

  • Any structural abnormality of the gastrointestinal (GI) tract (other than esophagitis or gastritis)
  • History of Crohn's disease, ulcerative colitis, diabetes mellitus, lactose malabsorption, malabsorption syndromes, celiac sprue, or any upper GI symptoms that may impact the assessment of IBS symptoms

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

200 participants in 3 patient groups, including a placebo group

Experimental Arm 1
Experimental group
Description:
ONO-2952 low dose every day for 4 weeks
Treatment:
Drug: ONO-2952
Experimental Arm 2
Experimental group
Description:
ONO-2952 high dose every day for 4 weeks
Treatment:
Drug: ONO-2952
Placebo Arm
Placebo Comparator group
Description:
ONO-2952 Matching Placebo every day for 4 weeks
Treatment:
Drug: ONO-2952 Matching Placebo

Trial contacts and locations

48

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems